Cargando…
A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinomas (PDACs) constitutively express the G-protein-coupled cholecystokinin B receptor (CCKBR). In this study, we identified DNA aptamers (APs) that bind to the CCKBR and describe their characterization and targeting efficacy. Using dual SELEX selection against “exposed” C...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312616/ https://www.ncbi.nlm.nih.gov/pubmed/27754762 http://dx.doi.org/10.1089/nat.2016.0621 |
_version_ | 1782508235247321088 |
---|---|
author | Clawson, Gary A. Abraham, Thomas Pan, Weihua Tang, Xiaomeng Linton, Samuel S. McGovern, Christopher O. Loc, Welley S. Smith, Jill P. Butler, Peter J. Kester, Mark Adair, James H. Matters, Gail L. |
author_facet | Clawson, Gary A. Abraham, Thomas Pan, Weihua Tang, Xiaomeng Linton, Samuel S. McGovern, Christopher O. Loc, Welley S. Smith, Jill P. Butler, Peter J. Kester, Mark Adair, James H. Matters, Gail L. |
author_sort | Clawson, Gary A. |
collection | PubMed |
description | Pancreatic ductal adenocarcinomas (PDACs) constitutively express the G-protein-coupled cholecystokinin B receptor (CCKBR). In this study, we identified DNA aptamers (APs) that bind to the CCKBR and describe their characterization and targeting efficacy. Using dual SELEX selection against “exposed” CCKBR peptides and CCKBR-expressing PDAC cells, a pool of DNA APs was identified. Further downselection was based on predicted structures and properties, and we selected eight APs for initial characterizations. The APs bound specifically to the CCKBR, and we showed not only that they did not stimulate proliferation of PDAC cell lines but rather inhibited their proliferation. We chose one AP, termed AP1153, for further binding and localization studies. We found that AP1153 did not activate CCKBR signaling pathways, and three-dimensional Confocal microscopy showed that AP1153 was internalized by PDAC cells in a receptor-mediated manner. AP1153 showed a binding affinity of 15 pM. Bioconjugation of AP1153 to the surface of fluorescent NPs greatly facilitated delivery of NPs to PDAC tumors in vivo. The selectivity of this AP-targeted NP delivery system holds promise for enhanced early detection of PDAC lesions as well as improved chemotherapeutic treatments for PDAC patients. |
format | Online Article Text |
id | pubmed-5312616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53126162017-03-06 A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma Clawson, Gary A. Abraham, Thomas Pan, Weihua Tang, Xiaomeng Linton, Samuel S. McGovern, Christopher O. Loc, Welley S. Smith, Jill P. Butler, Peter J. Kester, Mark Adair, James H. Matters, Gail L. Nucleic Acid Ther Original Articles Pancreatic ductal adenocarcinomas (PDACs) constitutively express the G-protein-coupled cholecystokinin B receptor (CCKBR). In this study, we identified DNA aptamers (APs) that bind to the CCKBR and describe their characterization and targeting efficacy. Using dual SELEX selection against “exposed” CCKBR peptides and CCKBR-expressing PDAC cells, a pool of DNA APs was identified. Further downselection was based on predicted structures and properties, and we selected eight APs for initial characterizations. The APs bound specifically to the CCKBR, and we showed not only that they did not stimulate proliferation of PDAC cell lines but rather inhibited their proliferation. We chose one AP, termed AP1153, for further binding and localization studies. We found that AP1153 did not activate CCKBR signaling pathways, and three-dimensional Confocal microscopy showed that AP1153 was internalized by PDAC cells in a receptor-mediated manner. AP1153 showed a binding affinity of 15 pM. Bioconjugation of AP1153 to the surface of fluorescent NPs greatly facilitated delivery of NPs to PDAC tumors in vivo. The selectivity of this AP-targeted NP delivery system holds promise for enhanced early detection of PDAC lesions as well as improved chemotherapeutic treatments for PDAC patients. Mary Ann Liebert, Inc. 2017-02-01 2017-02-01 /pmc/articles/PMC5312616/ /pubmed/27754762 http://dx.doi.org/10.1089/nat.2016.0621 Text en © Gary A. Clawson, et al., 2017; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Original Articles Clawson, Gary A. Abraham, Thomas Pan, Weihua Tang, Xiaomeng Linton, Samuel S. McGovern, Christopher O. Loc, Welley S. Smith, Jill P. Butler, Peter J. Kester, Mark Adair, James H. Matters, Gail L. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma |
title | A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma |
title_full | A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma |
title_fullStr | A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma |
title_short | A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma |
title_sort | cholecystokinin b receptor-specific dna aptamer for targeting pancreatic ductal adenocarcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312616/ https://www.ncbi.nlm.nih.gov/pubmed/27754762 http://dx.doi.org/10.1089/nat.2016.0621 |
work_keys_str_mv | AT clawsongarya acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT abrahamthomas acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT panweihua acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT tangxiaomeng acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT lintonsamuels acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT mcgovernchristophero acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT locwelleys acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT smithjillp acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT butlerpeterj acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT kestermark acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT adairjamesh acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT mattersgaill acholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT clawsongarya cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT abrahamthomas cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT panweihua cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT tangxiaomeng cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT lintonsamuels cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT mcgovernchristophero cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT locwelleys cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT smithjillp cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT butlerpeterj cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT kestermark cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT adairjamesh cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma AT mattersgaill cholecystokininbreceptorspecificdnaaptamerfortargetingpancreaticductaladenocarcinoma |